A case of sensory ataxic Guillain-Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer)
QJM
.
2022 Jan 21;115(1):25-27.
doi: 10.1093/qjmed/hcab296.
Authors
T Fukushima
1
,
M Tomita
1
,
S Ikeda
1
,
N Hattori
1
Affiliation
1
From the Department of Neurology, Toyota Kosei Hospital, 500-1 Ibobara Josui-cho, Toyota City JP470-0396, Japan.
PMID:
34871447
PMCID:
PMC8690109
DOI:
10.1093/qjmed/hcab296
No abstract available
Publication types
Case Reports
MeSH terms
BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Guillain-Barre Syndrome*
Humans
Immunoglobulin G
RNA, Messenger
SARS-CoV-2
Substances
COVID-19 Vaccines
Immunoglobulin G
RNA, Messenger
BNT162 Vaccine